Abbott Laboratories (NYSE:ABT) Holdings Decreased by Callan Capital LLC

Callan Capital LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 5.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,865 shares of the healthcare product maker’s stock after selling 239 shares during the quarter. Callan Capital LLC’s holdings in Abbott Laboratories were worth $425,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its position in Abbott Laboratories by 147.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 31,159 shares of the healthcare product maker’s stock worth $3,018,000 after acquiring an additional 18,546 shares during the last quarter. Strategic Blueprint LLC grew its position in Abbott Laboratories by 3.6% during the 3rd quarter. Strategic Blueprint LLC now owns 8,235 shares of the healthcare product maker’s stock worth $798,000 after acquiring an additional 286 shares during the last quarter. Stewart & Patten Co. LLC grew its position in Abbott Laboratories by 0.7% during the 3rd quarter. Stewart & Patten Co. LLC now owns 189,130 shares of the healthcare product maker’s stock worth $18,317,000 after acquiring an additional 1,240 shares during the last quarter. Financial & Tax Architects LLC grew its position in Abbott Laboratories by 3.8% during the 3rd quarter. Financial & Tax Architects LLC now owns 51,450 shares of the healthcare product maker’s stock worth $4,983,000 after acquiring an additional 1,905 shares during the last quarter. Finally, McGlone Suttner Wealth Management Inc. grew its position in Abbott Laboratories by 6.1% during the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 9,549 shares of the healthcare product maker’s stock worth $925,000 after acquiring an additional 553 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling

In related news, VP John A. Jr. Mccoy sold 472 shares of the firm’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $118.50, for a total transaction of $55,932.00. Following the sale, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 472 shares of Abbott Laboratories stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $118.50, for a total value of $55,932.00. Following the sale, the vice president now owns 18,760 shares of the company’s stock, valued at approximately $2,223,060. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrea F. Wainer sold 42,500 shares of Abbott Laboratories stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $112.50, for a total value of $4,781,250.00. Following the completion of the sale, the executive vice president now directly owns 65,027 shares in the company, valued at approximately $7,315,537.50. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,435 shares of company stock valued at $6,451,298. 1.10% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on ABT shares. Royal Bank of Canada decreased their price target on Abbott Laboratories from $128.00 to $125.00 and set an “outperform” rating on the stock in a research report on Thursday, April 18th. Raymond James reiterated a “buy” rating and issued a $124.00 price objective on shares of Abbott Laboratories in a research report on Wednesday. Barclays decreased their price objective on Abbott Laboratories from $141.00 to $140.00 and set an “overweight” rating on the stock in a research report on Monday. Evercore ISI increased their price objective on Abbott Laboratories from $120.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Citigroup increased their price objective on Abbott Laboratories from $126.00 to $128.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $121.50.

Abbott Laboratories Trading Up 0.6 %

Shares of ABT stock traded up $0.65 during trading hours on Friday, reaching $107.51. The company had a trading volume of 3,575,246 shares, compared to its average volume of 5,660,976. The company has a 50 day moving average of $113.64 and a 200 day moving average of $108.03. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.64 and a quick ratio of 1.16. The firm has a market cap of $186.55 billion, a price-to-earnings ratio of 33.49, a P/E/G ratio of 2.57 and a beta of 0.74. Abbott Laboratories has a 1-year low of $89.67 and a 1-year high of $121.64.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 17th. The healthcare product maker reported $0.98 EPS for the quarter, topping the consensus estimate of $0.96 by $0.02. The business had revenue of $9.96 billion for the quarter, compared to the consensus estimate of $9.88 billion. Abbott Laboratories had a return on equity of 20.32% and a net margin of 13.96%. The firm’s revenue was up 2.2% compared to the same quarter last year. During the same quarter last year, the business posted $1.03 EPS. On average, equities research analysts anticipate that Abbott Laboratories will post 4.62 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.05%. The ex-dividend date of this dividend is Friday, April 12th. Abbott Laboratories’s payout ratio is presently 68.54%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.